About 50% of tumor metastasis is via the lymphatic system, but the underlying mechanisms have not been characterized. L-selectin (CD62L) is a lymphocyte homing receptor that is important for the migration of lymphocytes into peripheral lymph nodes. 1 It is an intriguing question whether lymphoma cells use the same pathways of dissemination into peripheral lymph nodes. [2] [3] In this work, we sought to ascertain whether the expression of L-selectin on macrophage-like lymphoid neoplasm P388D1 cells would facilitate their localization to peripheral lymph nodes. 
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First, L-selectin mRNA in P388D1 cells and L-selectin protein on P388D1 cell surface were detected by reverse transcriptasepolymerase chain reaction (RT-PCR) and flow cytometry method (FCM) (data not shown), respectively, whereas C57BL/ 6 mouse splenic lymphocytes were used as a positive control of L-selectin expression (Figure 1a) . Then, L-selectin expressions on P388D1 cells were silenced by L-selectin small interferring RNA (siRNA) approach. In our experiment, both L-selectin siRNA, a target-specific 20-25 nt siRNA designed to knockdown L-selectin expression, and control siRNA which has no significant sequence homology with mRNA databases were from Santa Cruz Biotechnology, CA, USA. P388D1 cells were transfected with L-selectin siRNA and control siRNA, respectively, along with Effectene transfection reagent, following the manufacturer's instructions. After 30 h, L-selectin siRNA transfection dramatically reduced L-selectin expressions on P388D1 cells, whereas the control siRNA had no such effect (Figure 1b) . Further observation showed L-selectin expression did not recover to original level until 14 days after siRNA transfection (data not shown). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay showed L-selectin siRNA, control siRNA and the Effectene transfection reagent did not affect P388D1 cell growth curve, suggesting these regents have no cytotoxic effect on P388D1 cells. Similar results were observed after incubation of P388D1 cells with MEL-14 (anti-L-selectin mAB, BD Pharmagen (San Diego, CA, USA), Rat-immunoglobulin (IgG), (Sigma, St Louis, MO, USA) and carboxyfluorescein diacetate succinimidyl ester (CFSE) (Fluka, Deisenhofen, Germany), which were used in the experiments below ( Figure 1c) .
To analyse whether L-selectin mediates the adhesion of P388D1 cells to the lymphatic endothelium, Stamper-Woodruff assays were performed with little modification. 4 In brief, 3 Â 10 5 of P388D1 cells in 200-ml cell suspension was overlaid onto the frozen sections of DAB mouse lymph nodes, and the sections were maintained in static conditions for 15 min at 371C, followed by 5 min of rotation at 60 r.p.m., and thereafter again kept under static conditions for 15 min at 71C. The sections were fixed in 1% (v/v) glutaraldehyde for 5 min and stained with hematoxylin and eosin (HE) before the assay. In this experiment, P388D1 cells could adhere to both lymphatic sinusoids and marginal sinusoids (data not shown). The number of adherent cells on the sum of lymphatic sinusoids and marginal sinusoids was quantified by using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA). The results showed that the adherent cell number of P388D1 cell with MEL-14 (1:100) pretreatment was less than that with Rat IgG treatment, suggesting the adhesion of P388D1 cells to the sum of lymphatic sinusoids and marginal sinusoid in vitro can be blocked by L-selectin antibody (Figure 2a) . Furthermore, after L-selectin expression was reduced by L-selectin siRNA transfection, the adhesive ability of P388D1 cells to the sum of lymphatic sinusoids and marginal sinusoids decreased significantly, as compared with control siRNA transfection ( Figure 2a ). These data indicated that L-selectin on P388D1 cells mediates its adhesion to the lymphatic endothelium, and silencing L-selectin expression on P388D1 cells resulted in inhibition of adhesion of P388D1 cells to lymphatic sinusoids and marginal sinusoid in vitro. Next, we investigated whether siRNA-induced L-selectin expression silencing affect P388D1 cells adhesion on to lymphatic endothelium in vivo. For this purpose, P388D1 cells were labeled with 5 mM CFSE, a green fluorescence dye which can be transported across plasma membrane to react covalently with free amino group of intracellular macromolecules. 5 In brief, two groups of DAB mice (n ¼ 6) received footpad injections of CFSE-tagged P388D1 cells transfected with L-selectin siRNA or control siRNA, 1 Â 10 7 cells for each recipient. After 1À48 h, the mice were killed. Peripheral lymph nodes were removed and CFSE-tagged P388D1 cells in cell suspensions were evaluated by flow cytometry. A significant reduction of CFSE-tagged P388D1 cells population in popliteal nodes other than inguinal and axillary nodes was observed after 12 h in L-selectin siRNA-treated groups ( Figure 2b ). Similarly, two groups received footpad injections of CFSE-tagged P388D1 cells preincubated with 500 ng of MEL-14 or 500 ng of rat IgG, 1 Â 10 7 cells for each recipient. In the MEL-14-treated group, CFSE-tagged P388D1 cells adhesion to popliteal and inguinal nodes but not axillary nodes was significantly lower than that in the control group at 12 h (Figure 2b ). These data indicate that L-selectin on P388D1 cells plays an important role in adhesion to peripheral lymph nodes not only in vitro, but also in vivo.
Furthermore, to evaluate the effect of siRNA-induced L-selectin expression silencing on P388D1 cells metastasis in vivo, siRNA-transfected cells were injected into the footpad of each animal (n ¼ 7). The development of lymphoma in each group of mice was compared by constructing Kaplan-Meier survival curves. All non-killed mice died 28 days after the injection of 8 Â 10 5 P388D1 cells transfected with control siRNA, whereas the death of the mice was delayed significantly after injection of 8 Â 10 5 P388D1 cells transfected with L-selectin siRNA (Figure 2c ). The effect of L-selectin siRNAinduced L-selectin expression silencing was assessed by metastasis rates. The metastasis rates were defined as the proportion of mice, which had metastatic tumor in peripheral lymph nodes determined by standard histological analysis, Letters to the Editor within group. The results showed that silencing L-selectin expression by L-selectin siRNA dramatically attenuated metastasis of P388D1 cells to popliteal, inguinal and axillary nodes (Figure 2d) . In another experiment, 3 Â 10 6 P388D1-inoculated mice were injected with 500 ng of MEL-14 or 500 ng of rat IgG on the day of tumor inoculation and every 3 days thereafter (n ¼ 10). The mice were killed on day 21, and the effect of the antibody treatment was assessed by analysis of metastasis rates ( Figure 2d ). As compared with control group, the metastasis rate of P388D1 cells to inguinal and axillary nodes, but not popliteal nodes, was significantly reduced in MEL-14 treatment group. In footpad injection model, tumor cells can disseminate to popliteal, inguinal and axillary nodes successively. Our results suggest that a higher expression of L-selection correlates with a later time point of metastasis. Thus, inhibition of P388D1 cells adhesion to lymph node by silencing or blockade of L-selectin on cell surfaces attenuated P388D1 cell colonization in primary lymph nodes and dissemination to secondary lymph organs consequently as well.
Taken together, these results indicate that, similar to normal lymphocyte homing mechanisms, P388D1 cells transmigrate to lymph nodes by an L-selectin-dependent mechanism. L-selectin may be as a novel therapeutic target to cure some macrophagelike lymphoid neoplasms. from National Natural Science Foundation of China (30470400) and the Science and Technology Department of Liaoning Province, China. The somatic V617F point mutation, which activates the hematopoietic growth factor receptor-associated JAK2 tyrosine kinase, not only shows a high incidence in the BCR-ABLnegative chronic myeloproliferative disorders but also occurs in lower frequencies in other myeloid malignancies such as myelodysplastic syndrome (MDS) (in around 5% of all cases) or acute myeloid leukemia (AML) with overall incidences between 0.5 and 8% of all cases. [1] [2] [3] The distribution of the JAK2 mutations in the diverse cytogenetic and molecular subgroups of AML is not yet clarified. In the study of Lee et al.,
1 JAK2 mutations were found in only 3/113 patients leading to an incidence of 2.7%. They were represented in two of three cases by the classical V617F mutation, in one case by a K607N mutation. Both cases with a V617F were diagnosed as AML with the prognostically favorable reciprocal translocation t(8;21)(q22;q22)/AML1-ETO. 1 Based on these findings, we analyzed the JAK2 mutation status in 24 consecutive patients with AML with t(8;21)/AML1-ETO. Of these, 20 cases were diagnosed as untreated de novo AML, three cases showed therapy-associated AML (t-AML) after previous malignancies (two after treatment of breast cancer and one after seminoma) whereas one case had relapse of de novo AML. All cases underwent investigation by cytomorphologic evaluation in accordance with the FAB/WHO classification, cytogenetic analysis, interphase fluorescence in situ hybridization and molecular testing for the AML1-ETO gene fusion and JAK2 mutation as reported before. 3 A V617F mutation was found in two of the 24 cases (8%). Interestingly, both mutated cases were therapy-related after chemotherapy including antracyclines (AC: doxorubicin and cyclophosphamide) and topoisomerase inhibitors (PEB: cisplatin, ectoposide, bleomycin), respectively. The first patient was a 72-year-old woman with AML M1 5 years after breast cancer (peripheral leukocytes: 12 G/L; hemoglobin: 6.0 g/dL, thrombocytes: 60 G/L). The second patient was a 40-year-old male with AML M2 6 years after testicular seminoma (peripheral leukocytes: 16.3 G/L; hemoglobin: 8.4 g/dl; thrombocytes: 31 G/L). Thus, two of three cases with t-AML t(8;21)/AML1-ETO were JAK2 mutated in contrast to the 21 de novo patients who were all negative for the JAK2 mutation. These data for the first time suggest that JAK2 may be a typical additional aberration in AML with therapyrelated t(8;21)/AML1-ETO after treatment with antracyclines and topoisomerase inhibitors.
According to the two-hit model, 4 leukemogenesis in AML needs the cooperation of at least two different types of mutations: class I mutations induce myeloproliferation via activating mutations involving signal transduction pathways, whereas class II mutations are frequently represented by reciprocal gene fusions and lead to a stop of differentiation. The JAK2 mutation mediating increased activity of the JAK/STAT pathway and increased cell proliferation and survival 5 is conceived as class I mutation in accordance with this model. The AML1-ETO gene fusion, which is assumed to repress myeloid-specific promoters and suppress the transcriptional activation function of the normal AML1 gene, would represent a class II mutation in this context. In the previous study by Lee et al.,
1 it was not annotated whether the two cases with t(8;21)/ AML1-ETO were de novo or therapy-related AML. However, these two cases together with our two cases with JAK2 mutated t(8;21)/AML1-ETO AML suggest that the JAK2 mutation cooperates as class I mutation in leukemogenesis with t(8;21)/ AML1-ETO as class II mutation and this may be true especially for therapy-related AML. Also in de novo AML with t(8;21)/ AML1-ETO class I mutations such as FLT3, KIT or NRAS, mutations were found at relatively high frequencies, whereas they are rarely detected in t-AML.
6,7 Thus, we suggest that the occurrence of JAK2 mutations in t-AML may be more a matter of pathogenesis than of function in a way that in contrast to other class I mutations JAK2 V617F may be inducible by tumoreliminating agents. Desta et al.
8 described two cases of t-MDS/ t-AML with the V617F mutation in normal karyotype and myeloproliferative features with splenomegaly. Thus, it should be supposed that the V617F mutation occurs in t-AML also in other cytogenetic subgroups and interacts with other yet unidentified cooperating mutations as well. In contrast to the two normal karyotype cases, both t(8;21) cases of our study did not show any myeloproliferative features with respect to peripheral blood counts and bone marrow morphology and did not present with splenomegaly.
Only the analysis of larger cohorts of de novo AML and t-AML with respect to V617F in distinct cytogenetic and molecular Letters to the Editor
